For the Inventor, By the Inventor

Enter assignee name

Canbas Co., Ltd.

USPTO Granted Patents = 15

CIPO Patents = 1

EPO Patents = 5

Forward Citations = 31

Loading Chart...

Loading Chart...

18 inventors (with patents filed for the assignee):

Takumi Kawabe (15 out of 17 patents)

Hidetaka Kobayashi (7 out of 9 patents)

Takuji Sato (5 out of 7 patents)

4. Sayaka Yamamoto (3 out of 3 patents)

5. Machiyo Ishigaki (2 out of 2 patents)

6. Yoko Hasegawa (2 out of 2 patents)

7. Masashi Suganuma (2 out of 2 patents)

8. Akira Asai (1 out of 5 patents)

9. Naohisa Ogo (1 out of 5 patents)

10. Daisuke Muraoka (1 out of 3 patents)

11. Naoki Mine (1 out of 1 patent)

12. Naoya Saito (1 out of 1 patent)

13. Keiichi Sakakibara (1 out of 1 patent)

14. Jonathan M Friedman (1 out of 1 patent)

15. Toshiyuki Hibino (1 out of 1 patent)

15 patents: Sort by Forward Citations

1. 12239714 - Phosphatidylserine-binding conjugates (2025-03-04),

2. 12209079 - IDO/TDO inhibitor (2025-01-28),

3. 10149887 - Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment (2018-12-11),

4. 9221872 - Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations (2015-12-29),

5. 8415357 - Compounds with anti-cancer activity (2013-04-09),

6. 8084454 - Compounds with anti-cancer activity (2011-12-27),

7. 7851592 - Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents (2010-12-14),

8. 7652042 - Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments (2010-01-26),

9. 7629364 - Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments (2009-12-08),

10. 7407985 - Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments (2008-08-05),

11. 7358046 - Sensitivity test to predict efficacy of anti-cancer therapies (2008-04-15),

12. 7125842 - Anti-fungal compounds and methods of use (2006-10-24),

13. 7030111 - Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments (2006-04-18),

14. 6995135 - Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments (2006-02-07),

15. 6881575 - Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents (2005-04-19),

CanBas Co., Ltd. is a pharmaceutical company specializing in the research and development of innovative cancer therapies. With a focus on precision medicine, CanBas aims to provide effective and personalized treatment options for patients diagnosed with various types of cancer. Through extensive research and clinical trials, CanBas has developed a diverse pipeline of novel drug candidates targeting specific molecular pathways involved in cancer growth and progression. The company is committed to making a significant impact on cancer treatment by harnessing the power of advanced science and technology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

15 Patents

#1 in Numazu

#3,367 in Japan

#38,743 in the World

Canbas Co., Ltd.

Forward Citations = 31

18 inventors:

Takumi Kawabe (15 out of 17 patents)

Hidetaka Kobayashi (7 out of 9 patents)

Takuji Sato (5 out of 7 patents)

4. Sayaka Yamamoto (3 out of 3 patents)

5. Machiyo Ishigaki (2 out of 2 patents)

Please report any incorrect information to support@idiyas.com

Loading…